International News

Drug Maker Aurobindo Receives $17 Million Contract From India's AIDS Control Organization

From Henry J. Kaiser Family Foundation

February 1, 2008

Pharmaceutical company Aurobindo Pharma on Thursday announced that it has received a contract worth 700 million Indian rupees, or about $17.8 million, from India's National AIDS Control Organisation, Reuters/Yahoo! Malaysia News reports. Under the contract, Aurobindo will supply NACO with three antiretroviral drugs (Nair, Reuters/Yahoo! Malaysia News, 1/31). According to Iris, the three antiretrovirals have received prequalification from the World Health Organization and FDA (Iris, 2/1). NACO provides access to no-cost first-line antiretrovirals to more than 105,000 HIV-positive people in its 127 antiretroviral clinics. The organization in November 2007 announced that beginning this year, it will provide about 5,000 HIV-positive people with access to second-line antiretrovirals (Kaiser Daily HIV/AIDS Report, 11/26/07).

Back to other news for February 2008

Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2008 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.

More HIV News

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

Donna Summer, Coming Out, and How AIDS Changed It All: A Blog Entry by Mark S. King

Buffalo Bills Player Tweets HIV Test Results: Over-Share or Encouraging? A Blog Entry by Kellee Terrell

Study Finds HIV Infection Is an Independent Risk Factor for Lung Cancer

Broad-Spectrum Antivirals: The Future of HIV Treatment?

How Did I Get Here?

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.